Clinical Post-Transplant Lymphoproliferative Disorders.

Q2 Medicine

Cardiovascular and Hematological Disorders - Drug Targets Pub Date : 2022-01-01 DOI:10.2174/1871529X22666220804155810

Ziba Aghsaeifard, Reza Alizadeh

引用次数: 0

Abstract

Post-transplant lymphoproliferative disorders (PTLDs) are characterized by hyperproliferation of B cells due to solid organ or allogeneic hematopoietic stem cell transplant. Based on histological findings, it is divided into 4 categories. Most PTLD patients are Epstein-Barr virus (EBV) positive. Additionally, aggressive immunosuppressive therapies can also lead to PTLD. Reducing immunosuppressive regimes, antivirals, monoclonal antibodies, chemotherapy, and radiotherapy are available therapeutic options, depending on the nature and phase of the disease. This review briefly highlights pathogenesis, risk factors, prevention, and therapeutic strategies regarding PTLDs.

查看原文本刊更多论文

临床移植后淋巴增生性疾病。

移植后淋巴细胞增生性疾病(ptld)的特点是由于实体器官或异体造血干细胞移植导致B细胞过度增殖。根据组织学表现分为4类。大多数PTLD患者是eb病毒(EBV)阳性。此外，积极的免疫抑制治疗也可导致PTLD。根据疾病的性质和阶段，减少免疫抑制方案、抗病毒药物、单克隆抗体、化疗和放疗是可用的治疗选择。本文综述了PTLDs的发病机制、危险因素、预防和治疗策略。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Cardiovascular and Hematological Disorders - Drug Targets Medicine-Cardiology and Cardiovascular Medicine

CiteScore

1.90

自引率

0.00%

发文量

期刊介绍： Cardiovascular & Hematological Disorders - Drug Targets aims to cover all the latest and outstanding developments on the medicinal chemistry, pharmacology, molecular biology, genomics and biochemistry of contemporary molecular targets involved in cardiovascular and hematological disorders e.g. disease specific proteins, receptors, enzymes, genes. Each issue of the journal contains a series of timely in-depth reviews written by leaders in the field covering a range of current topics on drug targets involved in cardiovascular and hematological disorders. As the discovery, identification, characterization and validation of novel human drug targets for cardiovascular and hematological drug discovery continues to grow.